D. Longpré

Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy

V. Nguyen, Réjean Thomas, N. Machouf, 2012, HIV clinical trials.

Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV

H. Trottier, V. Nguyen, Réjean Thomas, 2017, AIDS.

Circulating (1→3)-β-D-Glucan is associated with immune activation during HIV infection.

V. Martel-Laferrière, C. Tremblay, C. Chartrand-Lefebvre, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Argon plasma coagulation treatment of anal high‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study

D. Rouleau, J. Macleod, F. Coutlée, 2018, HIV medicine.

Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort

Réjean Thomas, D. Murphy, N. Machouf, 2015, PloS one.

Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression.

C. Tremblay, D. Rouleau, J. Routy, 2007, Clinical immunology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

P-01-066 PrEP in Montreal: good adherence, no seroconversion and no evidence of risk compensation

Réjean Thomas, N. Machouf, B. Trottier, 2016 .

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)

Réjean Thomas, C. Costiniuk, M. Jenabian, 2015, HIV clinical trials.